A Study of KT-621 Administered Orally to Adult Participants With Moderate to Severe Eosinophilic Asthma
Part of paid clinical trials in Long Beach, California.
- Sponsor
- Kymera Therapeutics, Inc.
- Study ID
- NCT07323654
- Phase
- PHASE2
- Status
- Recruiting
Conditions
- Eosinophilic Asthma
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - 75 Years
- Healthy Volunteers
- Not accepted
Interventions
- KT-621 — DRUGOral drug
- Placebo — OTHEROral placebo matched to KT-621
Study Details
This Phase 2b study is designed to evaluate the safety and efficacy of KT-621 in participants with uncontrolled moderate to severe eosinophilic asthma. The main goals of this study are to investigate how effective KT-621 is at treating uncontrolled moderate to severe eosinophilic asthma, the safety and tolerability of KT-621, and how KT-621 behaves in the body.
Key Dates
- Start date
- Jan 28, 2026
- Status verified
- Jan 2026
- Primary completion
- Dec 31, 2027
- Completion
- Dec 31, 2027
Study Design
- Enrollment
- 264 participants (estimated)
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- TREATMENT
Arms
- Experimental: Group 1: KT-621 Dose 1
- Experimental: Group 2: KT-621 Dose 2
- Experimental: Group 3: KT-621 Dose 3
- Placebo Comparator: Group 4: Placebo
Primary Outcome Measure
Change from baseline in pre-bronchodilator FEV1 [ Time Frame: From baseline to Week 12 ]
Central Contacts
- Kymera Medical Director857-285-5300
Locations (20)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Kymera Investigative Site | Long Beach | California | 90815 | - |
| Kymera Investigative Site | Northridge | California | 91324 | - |
| Kymera Investigative Site | Redding | California | 96001 | - |
| Kymera Investigative Site | Upland | California | 91786 | - |
| Kymera Investigative Site | Loxahatchee Groves | Florida | 33470 | - |
| Kymera Investigative Site | Miami | Florida | 33126 | - |
| Kymera Investigative Site | Miami | Florida | 33173 | - |
| Kymera Investigative Site | Tampa | Florida | 33607 | - |
| Kymera Investigative Site | East Point | Georgia | 30344 | - |
| Kymera Investigative Site | Iowa City | Iowa | 52242 | - |
| Kymera Investigative Site | Chapel Hill | North Carolina | 27517 | - |
| Kymera Investigative Site | Toledo | Ohio | 43617 | - |
| Kymera Investigative Site | Edmond | Oklahoma | 73034 | - |
| Kymera Investigative Site | Clackamas | Oregon | 97015 | - |
| Kymera Investigative Site | Pittsburgh | Pennsylvania | 15241 | - |
| Kymera Investigative Site | North Charleston | South Carolina | 29406 | - |
| Kymera Investigative Site | Rock Hill | South Carolina | 29732 | - |
| Kymera Investigative Site | Chattanooga | Tennessee | 37403 | - |
| Kymera Investigative Site | Dallas | Texas | 75209 | - |
| Kymera Investigative Site | McKinney | Texas | 75069 | - |
Find similar trials in Long Beach, CA
Related Studies
- Randomised Clinical Trial to Investigate Efficacy and Safety of Benralizumab 30 mg SC as an add-on Therapy in Uncontrolled Eosinophilic Asthma Patients Treated With Medium-dose ICS-LABA Compared to Conventional Escalation to High-dose ICS-LABA TreatmentPHASE3 · Recruiting · AstraZeneca · Chandler, Arizona